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Abstract 
PURPOSE: This study was designed to analyze the characteristics and the quality of reporting of 
randomized, controlled trials published during the last ten years on fecal incontinence. 
METHODS: An electronic search for all randomized, controlled trials on fecal incontinence was 
undertaken by using the MEDLINE database via PubMed. The data collected were divided into 
general data, characteristics of reporting, methodology quality assessment using the Jadad scale and 
a validated methodology quality score (MINCIR score), evaluation of the items published in the 
CONSORT statement, and the journal impact factor. Reports were divided into two groups: 
published articles from 1996 to 2000 (Group 1), and from 2001 to 2005 (Group 2). 
RESULTS: Forty-two trials fulfilled the inclusion criteria of the study (Group 1, n = 15; and Group 2, n 
= 27). There were no significant differences in general characteristics of randomized, controlled trials 
between the two groups. In Group 2, there were a statistically significant higher number of studies 
that reported a flow chart (P < 0.001), written informed consent (P = 0.008), sample size calculation 
(P = 0.023), and withdrawals and dropouts (P < 0.001). We found a statistically significant higher 
score in Jadad scale (P = 0.046) and MINCIR score (P = 0.016) in the published studies in Group 2. 
Also we found higher journal impact factor of journals that published these randomized, controlled 
trials during the most recent years (P = 0.04). 
CONCLUSIONS: There is a lack of high-quality reported randomized, controlled trials on fecal 
incontinence during the last ten years. Reports of randomized, controlled trials involving patients 
with fecal incontinence published after 2001 were better reported than in the previous five years. 
Introduction 
Fecal incontinence is a significant health care problem with more than 5 percent of community-
dwelling adults reporting symptoms and approximately 1 percent experiencing symptoms that 
restrict their life.1 For many years evidence-based medicine has been considered the main way to 
advance clinical practice, replacing the traditional medical paradigm,  which  was based  on  
authority  and  expert opinion.2 Evidence-based medicine primarily uses randomized, controlled  
trials  to  clarify the  scientific basis for medical practice. A report of a randomized, controlled trial 
(RCT) should convey to the reader in a transparent manner why the study was undertaken and how 
it was conducted and analyzed.3 The assessment of the methodologic quality of a trial is closely 
intertwined with the quality of reporting, that is, the extent to which a report provides information 
about the design, conduct, and analysis of the trial.4 
In 1996, two groups of journal editors, trialists, and methodologists independently published  some  
recommendations on the reporting of trials.5 Later these two groups developed a common set of 
recommendations called a CONSORT statement (Consolidated Standards of Reporting Trials).3 The 
CONSORT statement comprises a checklist of essential items that should be included in reports of 
RCTs and a diagram for documenting the flow of participants through a trial. The objective of 
CONSORT was to facilitate critical appraisal and interpretation of RCTs by providing guidance to 
authors, peer reviewers, and editors about how to improve the reporting of their trials.5 Many major 
journals now insist on compliance with CONSORT when publishing RCTs 
Despite all these considerations, RCTs still are not being reported adequately.3 Inadequate reporting 
makes the interpretation of RCT results difficult and borders on unethical practice when biased 
results receive false credibility. 3 Although several studies have analyzed the quality of reports of 
RCTs in some areas of medicine, to our knowledge no study has evaluated the characteristics of RCTs 
published on fecal incontinence and analysed evolution in reporting over the time.6–8 This study was 
designed to analyze the characteristics and the quality of reporting of randomized, controlled trials 
(RCTs) published during the last ten years on fecal incontinence. 
METHODS 
Identification Criteria 
An electronic search for all randomized, controlled trials (RCTs) on fecal incontinence was 
undertaken by using the MEDLINE database via PubMed. The term “fecal incontinence” was 
searched as the main text item. Additional search strategies included: the selection “randomized 
controlled trial” as a type of article and publication from January 1, 1996 to December 31, 2005. Two 
researchers (DP and  CN) independently evaluated the studies that were eligible according to the 
identification criteria. 
Inclusion and Exclusion Criteria 
All studies found by the identification criteria, which focused on adult patients, were included. 
Nonrandomized trials, duplicated articles, or articles that presented data from a previously 
published RCT were excluded from the analysis. Articles in which the main outcome was not related 
to fecal incontinence but were identified by the search also were excluded from the study (e.g., 
treatment of anal fissure). Studies in which the main outcome was not fecal incontinence but some 
specific items related to this field were in the secondary outcomes were considered by coauthors 
and were included only if there was a general agreement about its relevance. 
Data Collection 
The available studies were read in detail, analyzed, and data were extracted. The data collected 
were divided into general data, characteristics of reporting, and methodology quality assessment. 
General Characteristics of the Articles 
In this section we included: the country of authors (or main author), the name of the journal, main 
fecal incontinence issue explored in the article (diagnosis, therapeutics, prevention, and follow-up), 
and whether a specific design was used (multicenter, double-blinded, cross-over, or placebo-
controlled trial). 
Characteristics of Reporting 
In this section, we looked for the specific inclusion of: description of method of randomization, total 
number of patients randomly assigned in the study, total number of patients followed during the 
study, presence of a flow diagram, comments on ethical approval, on written informed consent, and 
finally any reference to type of support or sponsorship for the study (e.g., grant). 
Quality Methodology Assessment and Journal Impact Factor 
All included articles were assessed by using three systems: the Jadad scale,9 a validated methodology 
quality score (MINCIR score),10 and a modified evaluation of the items published in the CONSORT 
statement.6  
Jadad scale is a five-point scoring system that includes three items to assess the methods used to 
generate random assignments, methods of double-blind assessment, and a description of dropouts 
and withdrawals by intervention group.9 A score that represents the sum of the three items is 
generated, with a final score that can vary from 0 to 5 points: 0 points are for the worst methods 
used, and 5 points are for the best. This scale was first described for assessment of pain studies, but 
because it incorporates components that are directly related to the control of bias, it has been used 
recently in other topics.7,9 
A valid and reliable scale of methodologic quality (MINCIR score) also was used.11 This scale is 
composed of three items: the first is related to the study design, the second to the population 
sample size in the study (adjusted according to the presence or absence of a sample size 
justification), and finally the third part is related to the methodology used in the reporting paper 
(objective, design, eligibility criteria, and their justification). According to this, a score which 
represents the sum of the three items that is generated, with a final score that can vary between 6 
and 36 points, with 6 points being the worst methodologic quality study and 36 points being the best 
(Table 1). 
Data extraction based on CONSORT reporting items were used as previously published.3 As Kober et 
al.6 published recently, we did not consider items that are mainly relevant for assessing external 
validity of a study because our goal was to analyze the reporting level of items that are important to 
assess potential biases. This evaluation included 12 of 22 items of the CONSORT statement as 
described by Kober et al. 6 and an additional item, namely conflict of interest, which is considered 
relevant to reflect general transparency in scientific writing.3,6 Items were investigated for the 
available information by whether they were specifically reported in the article rather than whether 
they were performed during the trial.  
Finally, we analyzed the journal impact factor of every journal that published each RCT included in 
this study.12 The journal impact factor was extracted from the last updated SCI (Science Citation 
Index) version available. 
Two investigators (DP and SC) completed the quality assessment independently and blinded to each 
other’s result. Discrepancy between evaluations was solved by discussion and, if there was a lack of 
agreement, by the final decision of the senior author (CN). 
Statistical Analysis 
Data were entered into a database and were analyzed by using SPSS\ for Windows v. 10 statistical 
package (SPSS, Inc., Chicago, IL). To test the effect of time of publication in the quality of reporting of 
RCT data, reports were divided into two groups: published articles from January 1, 1996 to 
December 31, 2000 (Group 1), and published articles from January 1, 2001 to December 31, 2005 
(Group 2). 
Continuous data were presented as a median and range in parentheses. To avoid any bias related to 
the asymmetrical distribution of the scores, we also used a percentile range (25th and 75th 
percentile). Categorical data were presented as absolute numbers or percentages. 
Categorical data were compared by using the Pearson chi-squared test if at least 80 percent of the 
cells had an expected count of five or more and all cells had an expected count of more than one. If 
this assumption did not hold, Fisher’s exact test was used. The continuous data were analyzed using 
nonparametric tests (Mann-Whitney U test). Finally, the correlation between scoring systems and 
journal impact factor were explored by Spearman’s correlation test. A bilateral P value<0.05 was 
considered statistically significant 
RESULTS 
Between January 1996 to December 2005, 2,844 articles were published and appeared in PubMed 
using the search term“fecal incontinence” (2,398 in English). Of those, there were 115 RCTs (4.1 
percent), 524 reviews (18.4 percent), 287 clinical trials (10.1 percent), 121 letters (4.2 percent), 55 
editorials (1.9 percent), 14 meta-analyses (0.5 percent), and the remaining were nonclassifiable into 
one of the previous groups. 
Forty-two of the 115 RCTs fulfilled the inclusion criteria of the present review (Group 1, n=15; and 
Group 2, n=27) and 73 did not. Sixty articles were excluded because although there was some 
information on fecal incontinence, this was not sufficient to be evaluated in the study. The mainissue 
of these excluded articles were: colonic or ileal pouch (n=16), chronic anal fissure (n=11), 
hemorrhoidal disease (n=10), pelvic radiotherapy (n=8), fistula-in-ano (n=4), community care (n=4), 
menopause (n=1), prostate disease (n=1), colonoscopy (n=1), colonography (n=1), classification of 
stools (n=1), constipation (n=1), and diagnosis of bowel disorders (n=1). Thirteen articles were 
excluded for other reasons: seven articles because they were not randomized or the data were 
extracted from a previously reported RCT; five articles because they focused on children; and one 
article was a study of cadavers. The appendix shows a list of the 42 RCTs that were included in the 
present study 
Table 2 shows the general characteristics of the included articles according to the period of 
publication. The United Kingdom was the most common source of articles on fecal incontinence; an 
American journal (Diseases of the Colon & Rectum) was the journal that published the most RCTs on 
fecal incontinence that fulfilled the inclusion criteria. The most common focus in the series was RCTs 
on treatment. Only in the last five years (Group 2) did we find multicentre trials that fulfilled the 
inclusion criteria. There were no statistically significant differences in the general characteristics 
between the two groups. 
Table 3 shows the reported characteristics of the included articles and their quality assessment. In 
Group 2, there were a statistically significant higher number of articles that reported a 
comprehensive flow chart diagram of patients evaluated for the study (P<0.001) and a specific 
comment about written, informed consent (P=0.008). However, there were no statistical differences 
in the method of allocation sequence, the number of patients who were randomly assigned in all the 
studies, the number of patients who completed the trials, comments on ethical approval, and type 
of support for the study. When we evaluated the quality of reporting of RCTs we found a statistically 
significant higher score in Jadad score (P=0.046) and MINCIR score (P=0.016) in articles published 
during the last five years (Group 2). Also we found higher median of the journal impact factor of 
journals that published RCTs on fecal incontinence during the most recent years (P=0.04). 
Figure 1 shows the statistically significant lineal correlation between the two methods (Jadad scale 
and MINCIR score) of evaluating the quality of the reporting of RCTs (Rho=0.654, P<0.001). Also we 
found a correlation between the journal impact factor and Jadad scale (Rho=0.315, P= 0.048) and 
journal impact factor and MINCIR score (Rho=0.432, P=0.005). 
Table 4 shows the frequency of reporting of 12 selected CONSORT items and conflict of interest item 
in the RCTs. The only statistically significant difference between Groups 1 and 2 was a higher 
proportion with any reference to sample size calculation (P=0.023) and withdrawals and dropouts 
(P<0.001) in Group 2. 
DISCUSSION 
The clinical management of fecal incontinence is evolving.During the last ten years, more than 2,800 
articles were published on this issue; however, interestingly only 4 percent of them were 
randomized, controlled trials (RCTs). In recent years, this type of study has become more common 
than it was ten years ago. For example, when we did the PubMed search we found that the number 
of RCTs on fecal incontinence was 6 in 1997, 14 in 2000, and 21 in 2005. However we also noted that 
most RCTs retrieved using the search term “faecal incontinence”, did not have their main focus on 
faecal incontinence. 
An RCT is considered the “standard” for establishing clinical effectiveness because it is well known 
that it minimizes bias.3 Therefore, RCT methods represent a key research activity, with the potential 
to improve the quality of health care and control costs through careful comparison of any 
alternatives.6 Given the limited number of RCTs on fecal incontinence, the methodologic limitations 
of the reports and the social importance of this condition it seemed timely to conduct a bibliometric 
analysis using comprehensive methodological quality assessment. This was our main objective for 
this study. 
Studies in all areas of investigation, including prevention or diagnosis of fecal incontinence, are 
warranted. Interestingly, there were a high number of trials that focused on therapeutic issues 
rather than other important issues, such as diagnosis. These findings were not different from other 
areas. For example, in a single-year analysis of RCTs in six well-known medical journals, more than 60 
percent of trials evaluated pharmacologic interventions.13 It is known that commercial interests, 
which fund many treatments, influence the interests of researchers and probably the conduct of 
RCTs. 
Given the huge number of studies published annually in all areas of medicine, to keep up to date a 
clinician, according to one study, would need to read approximately 17 articles per day, every day of 
the year.14 Therefore, easy to-use tools that evaluate the overall quality of articles could significantly 
improve the efficiency of clinical readers. 
Quality is a multidimensional concept, which could relate to design, conduct, analysis of a trial, its 
clinical relevance, or quality of reporting.15 We have enough information to support the idea that the 
methodologic quality of a trial is directly related to the quality of reporting.4 Reports should provide 
information about the design, conduct, and analysis of the trial.15 Most readers assume that the 
quality was inadequate unless the information to the contrary is provided.15 This often is justified 
because faulty reporting generally reflects faulty methods.16 It also is interesting that lower quality 
studies are more likely to report positive results.5 Moreover, we should note that a well-conducted, 
but badly reported, trial can be misclassified, and therefore, the quality of a RCT is of obvious 
relevance to systematic reviews and meta-analyses.15 
There have been several attempts to evaluate the quality of reports using special tools. The journal 
impact factor was created in the early 1960s to help select journals for the Science Citation Index 
(SCI) and as a simple method for comparing journals regardless of their size.12 This score is based on 
two elements: 1) the numerator, which is the number of citations in the current year of any items 
published in a journal during the previous two years, and 2) the denominator, which is the number 
of substantive articles (source items) published during the same two years.12 The use of journal 
impact factor has evolved and has been used as a measure of quality on authors’ curriculum vitae. 
However, the practical value and its utility have been recently questioned. 12 Moreover, there are a 
number of other methods for quantifying the quality of trials, including the use of scores.9,10 The use 
of these scores permits a quick evaluation for the reader but previously the relationship between 
these quality scores and journal impact factor was unknown. We used two scores that have not 
previously been reported together to evaluate reporting quality on fecal incontinence. Interestingly, 
and despite the fact that the Jadad scale was described for use only for RCTs, it was statistically 
significantly correlated with the MINCIR score, which is not only for these types of studies. We found 
a statistical significant higher score from both systems in recent years. Thus, this information 
supports the idea that there have been more RCTs about fecal incontinence in recent years and they 
also have been better reported. 
Some initiatives in the era of evidence-based medicine have tried to increase the quality of reporting 
of RCTs. The objective of CONSORT was to facilitate critical appraisal and interpretation of RCTs by 
providing guidance to authors, peer reviewers, and editors about how to improve the reporting of 
their trials.5 However, we noted that even in the most recent years (from 2001–2005) some basic 
descriptions in a RCT, as well as the method of randomization, are still insufficiently reported. It 
might be reasonable to exclude such RCTs from reviews or meta-analyses if the quality of reporting 
is poor.  
Journal policies influence the quality of reporting. They each have different standards set for 
manuscript submission, different editorial processes, variation in values and emphasis among 
journals, and international differences in research cultures.8 However, we found, for example, that 
only Diseases of the Colon & Rectum, Journal of the American Geriatrics Society, and The American 
Journal of Obstetrics and Gynaecology published more than three RCTs about fecal incontinence 
during the period of the study. Therefore, it was impossible to compare the different quality of 
reporting  of each journal. However, to explore the relationship between journals and quality of 
report we added to the quality assessment by scores its relationship to journal impact factor. 
Moreover, we found a statistical correlation between Jadad and MINCIR scores and journal impact 
factor. There is no doubt that journals influence making explicit quality requirements for the 
documentation of RCTs. 
CONCLUSIONS 
Our results indicate that there is a lack of high-quality reported RCTs in fecal incontinence during the 
last ten years in all areas. We found that reports of RCTs involving patients with fecal incontinence 
published after 2001 were better reported. There are some quality methodologic scores that provide 
some assistance in the assessment of trials and they correlated to the quality of journals. Strategies 
to improve the quality of reporting studies are warranted 
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Table 1: Methodologic quality score (MINCIR score)10 
Item Score 
1. Study design 
Multicenter, clinical trial  
Randomized, clinical trial (double-blind)* 
Clinical trial (simple blind or nonblinded, 
nonrandomized)† 
Concurrent cohort studies  
Case-control studies and historic cohort studies 
Cross-sectional studies 
Case series 
 
12 
9 
6 
 
4 
3 
3 
1 
2. Studied population  x justification factor‡ 
≥201 
151–200 
101–150 
61–100 
31–60 
 
6 or 12 
5 or 10 
4 or 8 
3 or 6 
2 or 4 
≤30 1 or 2 
3. Methodology 
Objective 
Precise and definite objectives are presented  
Imprecise objectives are presented 
No objectives are presented 
Design 
The design used is mentioned and justified 
The design used is only mentioned 
The design used is neither mentioned nor justified 
Selection criteria 
Inclusion and exclusion criteria are described 
Inclusion or exclusion criteria are described 
No selection criteria are described 
Sample size 
Justified sample size 
Nonjustified sample size 
 
 
3 
2 
1 
 
3 
2 
1 
 
3 
2 
1 
 
3 
1 
Final score = ITEM 1+ITEM 2+ITEM 3 Score 6 to 36 
*Includes clinical trials with restricted randomization and quasi-experimental studies. _ 
†Includes experimental studies (prepost). _ ‡Justification factor is x 2 if the sample was justified and 
x 1 if it was a nonjustified sample size 
 
 
Table 2. General characteristics data of 42 randomized, controlled trials for fecal incontinence 
according to period of publication 
 Group 1 
1996–2000 
(n=15) 
Group 2 
2001–2005 
(n=27) 
P value* 
Country  
United Kingdom 
United States of America 
Australia 
Ireland 
Others 
 
5 (33.3)  
2 (13.3) 
1 (6.6) 
2 (13.3) 
5 (33.3) 
 
6 (22.2) 
5 (18.5) 
 4 (14.8) 
3 (11.1) 
9 (33.3) 
 
 
 
 
 
0.518 
Journal 
Dis Colon Rectum 
J Am Geriatr Soc 
Am J Obstet Gynecol 
Others 
 
8 (53.3)  
1 (6.6)  
1 (6.6) 
5 (33.3) 
 
4 (14.8)  
3 (11.1) 
2 (7.4) 
18 (66.7) 
 
 
 
 
0.383 
Main issue 
Diagnosis 
Therapeutics 
Prevention 
Follow-up 
 
1 (6.6) 
10 (66.7) 
4 (26.7) 
— 
 
— 
17 (62.9) 
9 (33.3) 
1 (3.7) 
 
 
 
 
0.44 
Type of RCT 
Multicenter trial 
Double-blinded trial 
Cross-over trial 
Placebo-controlled trial 
 
— 
3 (20) 
3 (20) 
3 (20) 
 
5 (18.5) 
4 (14.8) 
2 (7.4) 
1 (3.7) 
 
0.101 
0.608 
0.251 
0.077 
*Chi-squared test. _ Data are numbers with percentages in parentheses unless otherwise indicated. 
Table 3. Reporting characteristics and quality assessment of randomized, controlled trials 
according to period of publication 
 
 Group 1 
1996–2000 
(n=15) 
Group 2 
2001–2005 
(n=27) 
P value* 
Method of random allocation 
sequence 
Computer random 
Sealed envelopes only 
Table with random numbers 
Other 
No mention 
 
 
5 (33.3) 
2 (13.3)  
1 (6.6) 
1 (6.6) 
6 (40) 
 
 
16 (59.2) 
3 (11.1) 
1 (3.7) 
1 (3.7)  
6 (22.2) 
 
 
 
 
 
 
0.599* 
No. of patients randomly 
assigned 
No. of patients completed the 
study 
40 (11–206) 
 
39 (11–178) 
82 (10–2,088) 
 
 82 (8–1,596) 
0.128† 
 
0.253† 
 
Flow chart diagram — 14 (51.8) <0.001* 
Comments on ethical 
approval 
13 (86.7) 24 (88.9) 1* 
Written, informed consent 7 (46.7) 24 (88.9) 0.008* 
Support 
Grant 
Company 
No mention 
 
6 (40) 
3 (20) 
6 (40) 
 
16 (59.2) 
4 (14.8) 
7 (26) 
 
 
 
0.483* 
Jadad scale (maximum 5) 
Median (range) 
Percentile25th–75th 
 
2 (0–4) 
0–3 
 
3 (0–5) 
2–3 
 
0.046* 
 
MINCIR score (maximum 36) 
Median (range)  
Percentile25th–75th 
 
19 (13–25)  
15–20 
 
23 (13–36) 
 17–27 
 
0.016* 
 
Impact factor 
Median (range)  
Percentile25th–75th 
 
2.26 (1.79-4.71) 
2.26–3.08 
 
3.43 (1.38–23.5) 
2.26–6.09 
 
0.04* 
 
Data are numbers with percentages in parentheses or medianswith ranges in parentheses unless 
otherwise indicated. _ *Nonparametric test (Mann-Whitney U test). _ †Chi-squared test. 
 
 
Table 4. Frequency of reporting of 13 data items (modified CONSORT checklist) of the 42 
randomized, controlled trials for fecal incontinence by period of publication 
 
Item* Section and topic 
 
Group 1 1996–2000 
(n=15) 
Group 2 2001–
2005 (n=27) 
P value† 
 
1 Randomized in Title 
Abstract only 
No mention 
8 (53.3) 
 7 (47.7) 
— 
17 (62.8) 
9 (33.3) 
1 (3.7) 
 
 
0.561 
2 Scientific background and 
purpose described 
14/15 (93.3) 27/27 (100) 0.357 
4 Details of intervention in each 15/15 (100) 27/27 (100) NC 
arm  
7 Calculation of sample size 3/15 (20) 16/27 (59.2) 0.023 
8 Method of randomization 
described 
9/15 (60) 20/27 (74.1) 0.488 
9 Adequate concealment of 
allocation 
5/15 (33.3) 18/27 (66.7) 0.055 
12 Statistical methods described 15/15 (100) 26/27 (96.2) 1 
13 Withdrawals and dropouts 
reported 
2/15 (13.3) 22/27 (81.5) <0.001 
16 Intention to treat 3/10 (30) 3/14 (21.4) 0.764 
17 Primary outcomes 13/15 (86.7) 26/27 (96.2) 0.287 
19 Adverse events reported 10/11 (90.1) 12/17 (81.5) 0.466 
20 Summary of results 15/15 (100) 27/27 (100) NC 
NI Conflict of interest declaration 2/15 (13.3) 5/27 (18.5) 1 
NC=not compared; NI=not included in CONSORT. _ Data are numbers with percentages in 
parentheses unless otherwise indicated. _ *Item number according to CONSORT checklist.3 _ †Chi-
squared test. 
 
 
Figure 1: Results of the Spearman’s correlation test between JADAD scale score and MINCIR score 
in the evaluation of reporting quality methodology of the randomized, controlled trials included. 
 
